| Title: | Maternal fatigue after postpartum anemia treatment with intravenous ferric carboxymaltose vs. intravenous ferric derisomaltose vs. oral ferrous sulphate : a randomized controlled trial |
|---|
| Authors: | ID Bombač Tavčar, Lea (Author)
ID Hrobat, Hana (Author)
ID Gornik, Lea (Author)
ID Preložnik Zupan, Irena (Author)
ID Vidmar Šimic, Marijana (Author)
ID Pečlin, Polona (Author)
ID Kavšek, Gorazd (Author)
ID Lučovnik, Miha (Author) |
|---|
| Files: |  PDF - Presentation file, download (435,60 KB)
MD5: CFFCFE19BFE5C6CC2D1130E08FD96D34
 URL - Source URL, visit https://www.mdpi.com/2077-0383/13/3/758
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | (1) Background: Postpartum anemia is a common maternal complication and is recognized as a cause of impaired quality of life, reduced cognitive abilities, and fatigue. Efficient iron supplementation for the treatment of postpartum anemia is an essential component of high-quality maternal care. The optimal mode of iron supplementation has not been determined yet, whether oral or intravenous. The objective of this study was to compare postpartum anemia treatment with intravenous ferric carboxymaltose, intravenous ferric derisomaltose, and oral ferrous sulfate. (2) Methods: A single-center, open-label, randomized controlled trial. Women with hemoglobin < 100 g/L within 48 h postpartum were randomly allocated to receive intravenous ferric carboxymaltose, intravenous ferric derisomaltose, or oral ferrous sulfate. Intravenous iron was given in one or two doses, while ferrous sulfate was given as two 80 mg tablets once daily. The primary outcome was maternal fatigue measured by the Multidimensional Fatigue Inventory (MFI) six weeks postpartum. Hemoglobin, ferritin, and transferrin saturation levels were analyzed as secondary outcomes. A Kruskal–Wallis test was used for group comparison (p < 0.05 significant). (3) Results: Three hundred women were included. The MFI score at six weeks postpartum did not differ between groups (median 38 (inter-quartile range (IQR) 29–47) in the ferric carboxymaltose group, median 34 (IQR 26–42) in the ferric derisomaltose group, and median 36 (IQR 25–47) in the ferrous sulfate group; p = 0.26). Participants receiving oral iron had lower levels of hemoglobin (135 (131–139) vs. 134 (129–139) vs. 131 (125–137) g/L; p = 0.008), ferritin (273 (198–377) vs. 187 (155–246) vs. 24 (17–37) µg/L; p < 0.001) and transferrin saturation (34 (28–38) vs. 30 (23–37) vs. 24 (17–37) %; p < 0.001) than those receiving ferric carboxymaltose or ferric derisomaltose. (4) Conclusions: Intravenous ferric carboxymaltose, intravenous ferric derisomaltose, and oral ferrous sulfate had similar impacts on maternal fatigue at six weeks postpartum despite improved laboratory parameters in the intravenous groups. |
|---|
| Keywords: | postpartum anemia, fatigue, intravenous iron treatment, oral iron replacement, patient-centered outcome |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 1-10 |
|---|
| Numbering: | Vol. 13, iss. 7, [article no.] 758 |
|---|
| PID: | 20.500.12556/DiRROS-24480  |
|---|
| UDC: | 61 |
|---|
| ISSN on article: | 2077-0383 |
|---|
| DOI: | 10.3390/jcm13030758 |
|---|
| COBISS.SI-ID: | 226639875 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 19. 2. 2025;
|
|---|
| Publication date in DiRROS: | 01.12.2025 |
|---|
| Views: | 143 |
|---|
| Downloads: | 64 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
